HomeCompareDMTK vs PFE

DMTK vs PFE: Dividend Comparison 2026

DMTK yields 2127.66% · PFE yields 6.20%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 DMTK wins by $17707088693.32M in total portfolio value
10 years
DMTK
DMTK
● Live price
2127.66%
Share price
$0.09
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$17707088693.38M
Annual income
$16,208,512,607,342,262.00
Full DMTK calculator →
PFE
Pfizer Inc.
● Live price
6.20%
Share price
$27.76
Annual div
$1.72
5Y div CAGR
13.2%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$51.1K
Annual income
$27,210.54
Full PFE calculator →

Portfolio growth — DMTK vs PFE

📍 DMTK pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodDMTKPFE
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, DMTK + PFE cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
DMTK pays
PFE pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

DMTK
Annual income on $10K today (after 15% tax)
$180,851.06/yr
After 10yr DRIP, annual income (after tax)
$13,777,235,716,240,922.00/yr
PFE
Annual income on $10K today (after 15% tax)
$526.66/yr
After 10yr DRIP, annual income (after tax)
$23,128.96/yr
At 15% tax rate, DMTK beats the other by $13,777,235,716,217,794.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of DMTK + PFE for your $10,000?

DMTK: 50%PFE: 50%
100% PFE50/50100% DMTK
Portfolio after 10yr
$8853544346.71M
Annual income
$8,104,256,303,684,736.00/yr
Blended yield
91.54%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on PFE right now

DMTK
Analyst Ratings
3
Buy
4
Hold
Consensus: Hold
Price Target
$7.50
+7878.7% upside vs current
Range: $7.50 — $7.50
Altman Z
-8.4
Piotroski
4/9
PFE
Analyst Ratings
16
Buy
22
Hold
1
Sell
Consensus: Hold
Price Target
$27.50
-0.9% upside vs current
Range: $24.00 — $35.00
Altman Z
2.0
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

DMTK buys
1
PFE buys
0
PoliticianChamberTickerTypeAmountDate
Tom Malinowski🏢 House$DMTK▲ Buy$1,001 - $15,0002021-01-11
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricDMTKPFE
Forward yield2127.66%6.20%
Annual dividend / share$2.00$1.72
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%13.2%
Portfolio after 10y$17707088693.38M$51.1K
Annual income after 10y$16,208,512,607,342,262.00$27,210.54
Total dividends collected$17601219228.91M$60.1K
Payment frequencyquarterlyquarterly
SectorStockHealthcare
Analyst consensusHoldHold
Analyst price target$7.50$27.50

Year-by-year: DMTK vs PFE ($10,000, DRIP)

YearDMTK PortfolioDMTK Income/yrPFE PortfolioPFE Income/yrGap
1← crossover$223,466$212,765.96$9,161$701.38+$214.3KDMTK
2$4,682,655$4,443,546.58$8,610$859.79+$4.67MDMTK
3$92,031,981$87,021,539.62$8,366$1,081.25+$92.02MDMTK
4$1,696,889,334$1,598,415,114.79$8,483$1,405.66+$1696.88MDMTK
5$29,359,261,977$27,543,590,390.03$9,084$1,907.24+$29359.25MDMTK
6$476,792,027,971$445,377,617,654.91$10,418$2,732.78+$476792.02MDMTK
7$7,269,883,644,738$6,759,716,174,809.65$13,007$4,193.56+$7269883.63MDMTK
8$104,104,693,867,782$96,325,918,367,911.80$18,010$7,005.87+$104104693.85MDMTK
9$1,400,538,398,162,041$1,289,146,375,723,514.20$28,216$12,979.89+$1400538398.13MDMTK
10$17,707,088,693,375,648$16,208,512,607,342,262.00$51,081$27,210.54+$17707088693.32MDMTK

DMTK vs PFE: Complete Analysis 2026

DMTKStock

DermTech, Inc., a molecular diagnostic company, develops and markets novel non-invasive genomics tests to diagnosis skin cancer, inflammatory diseases, and aging-related conditions in the United States. It offers DermTech Melanoma Test (DMT), a gene expression test that enhances early detection of genomic atypia and helps rule out melanoma and the need for a surgical biopsy of atypical pigmented lesions. The company also provides adhesive skin sample collection kits, as well as gene expression assays for the Th1, Th2, IFN-gamma, and Th17 inflammatory pathways. In addition, it is developing UV damage DNA risk assessment products, as well as non-melanoma skin cancer diagnostic and cutaneous T-cell lymphoma rule out test products, as well as offering health-related and information services through electronic information and telecommunication technologies. The company sells its products primarily to pathology and oncology practitioners. DermTech, Inc. is headquartered in La Jolla, California.

Full DMTK Calculator →

PFEHealthcare

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Full PFE Calculator →
📬

Get this DMTK vs PFE comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

DMTK vs SCHDDMTK vs JEPIDMTK vs ODMTK vs KODMTK vs MAINDMTK vs JNJDMTK vs MRKDMTK vs ABBV

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.